Targeting Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Available and Future Pharmaceutical OptionsEmmanouil Koullias, Anastasia Thanopoulou, Maria Papavdi et al.|Cureus|2025Cited by 6
Addition of Dulaglutide or Empagliflozin to Standard-of-Care Treatment: Effect on Liver Steatosis in Patients With Type 2 Diabetes MellitusEmmanouil Koullias, John Koskinas, Maria Papavdi et al.|Cureus|2024Cited by 4